Global brain ischemia and reperfusion result in the degradation of the eukaryotic initiation factor (elF) 4G, which plays a critical role in the attachment of the mRNA to the ribosome. Because eIF-4G is a substrate of cal pain, these stud ies were undertaken to examine whether calpain I activation during global brain ischemia contributes to the degradation of eIF-4G in vivo. Immunoblots with antibodies against calpain I and eIF-4G were prepared from rat brain postmitochondrial supernatant incubated at 37°C with and without the addition of calcium and the calpain inhibitors calpastatin or MDL-28,170, Addition of calcium alone resulted in calpain I activation (as measured by autolysis of the 80-kDa subunit) and degradation Abbreviations used: elF-40, eukaryotic initiation factor 40; PMSF, phenylmethylsulfonyltluoride; SDS-PAOE, sodium dodecyl sulfate polyacrylamide gel electrophoresis.
The severe reduction of protein synthesis that occurs during early reperfusion after global brain ischemia arises from a defect in the formation of the translation initiation complex (Krause and Tiffany, 1993) . One step in this process, the attachment of mRNA to the 40S ribosomal subunit, is coordinated by the eukaryotic ini tiation factor 4F complex (eIF-4F) comprised of eIF-4A (an ATP-dependent RNA helicase), eIF-4E (which binds the mRNA m 7 GTP cap), and eIF-4G (which provides docking sites for the aforementioned proteins) (Merrick and Hershey, 1996) . Global brain ischemia and reperfu sion results in the alteration of several of these initiation factors (Hu and Wieloch, 1993; Burda et a!., 1994; Neu mar et aI., 1995; DeGracia et aI., 1996) . In particular we reported evidence of proteolysis of eIF-4G (also known of eIF-4G; this effect was blocked by either 1 ILmollL cal pastatin or 10 ILmollL MDL-28, 170, In rabbits subjected to 20 minutes of cardiac arrest, immunoblots of brain postmitochon drial supernatants showed that the percentage of autolyzed cal pain I increased from 1.9% ± 1.1% to 15.8% ± 5.0% and that this was accompanied by a 68% loss of eIF-4G. 170 pretreatment (30 mg/kg) decreased ischemia-induced ca1pain I autolysis 40% and almost completely blocked eIF-4G degra dation. We conclude that calpain I degrades eIF-4G during global brain ischemia. Key Words: Brain ischemia-Protein synthesis-Translation initiation factors-Calpain.
as eIF-4-y or p 220) after an ischemic insult (DeGracia et aI., 1996) . Moreover Etchison et ai. (1982) demonstrated that proteolytic loss of eIF-4G during poliovirus infec tion leads to inhibition of protein synthesis. The identity of the enzymes that degrade eIF-4G as a result of brain ischemia is unknown, but there is evidence that eIF-4G is a substrate of the calcium-activated protease calpain (Wyckoff et aI., 1990) , and we have shown that calpain I (fL-calpain) activation occurs during brain ischemia . Therefore these studies were un dertaken to examine whether calpain I activation during global brain ischemia contributes to the degradation of eIF-4G in vivo.
METHODS
Calpain I activation can be detected by the autolytic cleavage of the N-terminus of its 80-kDa catalytic subunit, which pro duces active fragments with molecular weight by electropho retic mobility (M,) of 76 and 78 kDa both in vitro (Croall et aI., 1992) and in vivo (Hayashi et aI., 1991; Saito et aI., 1993; Molinari et aI., 1994) . Monoclonal antibody against the 80-kDa catalytic subunit of human calpain I (clone B27D8), which reacts with the 76-, 78-, and 80-kDa forms of the calpain I catalytic subunit in rabbits (Neumar et aI., 1996) , was provided by John Elce (Queens University, Kingston, Ontario) (Samis et aI., 1987) . In our hands this antibody generated negligible sig nal with rat specimens. To measure calpain I autoly-sis in rats, an affinity-purified polyclonal antibody was pre pared against a 15-amino acid peptide corresponding to the N-terminal sequence of the rat calpain I catalytic subunit (Sori machi et aI., 1996) . This antibody recognizes the 80-kOa cata lytic subunit in rats, but has negligible reactivity with the au tolyzed forms. An affinity-purified polyclonal anti-eIF-4G an tibody was prepared against a conserved 16-amino acid peptide beginning at amino acid 327 in the human sequence (OeGracia et aI., 1996) . Purified porcine calpain I and recombinant do main I of human calpastatin, which specifically inhibits cal pain, were purchased from Calbiochem (La Jolla, CA, U.S.A.). MOL-28,170, a cell-permeant calpain inhibitor (Mehdi et aI., 1988) , was a gift from Shujaath Mehdi (Marion Merrell Oow Research Institute, Cincinnati, OH, U.S.A.). All other chemi cals were reagent grade. All animal experiments were approved by our institutional review board and were conducted following the' 'Principles of Laboratory Animal Care" (NIH publication No. 86-23, revised 1985) . For Western blots, 50-ILg protein samples were electropho resed on SOS-polyacrylamide gels (7.5% total acrylamide, 2.5% cross-linker bis acrylamide), transferred to nitrocellulose, immunoblotted with a 1 :500 dilution of the antibody against rat calpain I, and developed using enhanced chemiluminescence (ECL, Amersham, Arlington Heights, IL, U.S.A.). The mem branes were then stripped (in 100 mmollL 2-mercaptoethanol, 2% SOS, and 62.5 mmollL Tris, pH 6.7 at 50°C for 30 minutes) and reblotted with antibody against eIF-4G (I :750).
Ischemia-induced calpain I autoproleolysis and eIF-4G deg radation occUlTing in vivo were studied in female New Zealand white rabbits anesthetized with 4% halothane. Three rabbits were included in each of three treatment groups: (I) control Western blots were performed as described above except that a 1: 10,000 dilution of the antibody against human sequence calpain I was used. Tmmunoblot exposures were adjusted to insure linearity. Relative band densities were quantified by den sitometry, and differences between experimental groups were examined for significance by analysis of variance and Fisher's least significant difference posthoc comparison.
RESULTS

In vitro cal pain I autolysis and eIF-4G degradation
The antibodies to eIF-4G and the N-terminus of the rat cal pain I catalytic subunit identified the expected bands with Mr of 220 kDa and 80 kDa, respectively (Fig. 1) ; these signals were absent if the primary antibody was omitted or preblocked with the antigenic peptide. As pre viously stated in the methods section, the calpain I anti body generated from the human sequence protein did not generate adequate signal in our rat brain samples.
In the absence of added calcium, there was no detect able loss of the calpain I 80-kDa subunit or eIF-4G after 30 minutes' incubation ( Fig. 1, lanes 1-3) . Addition of calcium without a calpain inhibitor resulted in a rapid decrease of the calpain I 80-kDa subunit and degradation of eIF-4G (Fig. 1, lanes 4-6) . Simultaneous addition of calcium and either calpastatin or MDL-28,170 blocked the loss of the calpain I 80-kDa subunit and inhibited the degradation of eIF-4G (Fig. 1, lanes 7-12) .
In vivo calpain I autolysis and elF -4G degradation during complete global cerebral ischemia During in vivo brain ischemia, the unautolyzed calpain I catalytic subunit is identified as a predominant band with the expected Mr of 80 kDa identical to purified porcine calpain I, and the autolyzed forms appear with Mr of 76 and 78 kDa (Fig. 2, lane 1) ; this signal was absent if the primary antibody was omitted or preblocked with purified calpain I. The percentage of autolyzed cal pain I was estimated by dividing the density of the au tolyzed bands (76 kDa + 78 kDa) by the total calpain I band density (76 kDa + 78 kDa + 80 kDa). After 20 minutes' ischemia autolyzed cal pain I increased from 1.9% ± l.l% to 15.8% ± 5.0% (P = 0.001, Fig. 2) . Pretreatment with MDL-28170 decreased ischemia induced caJpain I autolysis to 9.5% ± 0.5% (P = 0.04 versus untreated 20-1) (Fig. 2) . The anti-eIF-4G immu nob lot of this same membrane shows that 20 minutes' ischemia induced a 68% loss of eIF-4G (Fig. 2 , lanes 5-7 and right graph, P = 0.004 versus controls) that was almost completely blocked by MDL-28,170 (Fig. 2 , lanes 8-10, P = 0.01 versus untreated 20-1). 1-3) . Although the addition of calcium (1 mmol/L in excess of EGTA) promptly causes the loss of calpain I and eIF-4G (lanes 4-6), this loss is prevented by calpastatin (1 �moI/L, lanes 7-9) or MDL-28,170 (1 0 �moIlL, lanes 10-12).
DISCUSSION
Cal pains have long been suspected to cause proteoly sis in the ischemic brain, and we have recently reported direct evidence of calpain I activation during complete global ischemia in vivo (Neumar et aI., 1996) . The cal pains (EC 3.4.22.17 ) are a family of nonlysosomal, cal cium-activated, neutral cysteine proteases, some of which are ubiquitously distributed while others are tis sue-specific (Saido et aI., 1994; Sorimachi et aI., 1994) . The ubiquitous forms, calpain I and calpain II, are pre sent in neurons (Fukuda et aI., 1990) , but no brain specific isoforms have yet been found (Sorimachi et aI., 1994) . Calpain I and II share a common 30-kDa regula tory subunit, but each has a unique 80-kDa catalytic sub unit. The calpains are absolutely dependent on Ca 2 + and are regulated by phospholipids, an endogenous inhibitor (calpastatin), and an activator protein (Croall and DeMartino, 1991) . A multitude of regulatory and cyto skeletal proteins known to be in vitro substrates of cal pain I are degraded during cerebral ischemia and reper fusion (Kishimoto et aI., 1989; Kitagawa et aI., 1989; Kuwaki et aI., 1989; Seubert et aI., 1989; Inuzuka et aI., 1990; Onodera et aI., 1990; Yanagihara et aI., 1990; Wieloch et aI., 1991; Tomimoto and Yanagihara, 1992; Yamamoto et aI., 1992; Kaku et aI., 1993; Neumar et aI., 1995) .
To determine whether calpain I activation during glob al brain ischemia contributes to the degradation of eIF-J Cereb Blood Flow Metab, Vol. 18, No. 8, 1998 4G in vivo, we used the calpain inhibitors calpastatin and MDL-28, 170 to demonstrate specificity in vitro and then used MDL-28,170 to show efficacy in vivo. Calpastatin is the specific physiologic inhibitor of calpain. It does not inhibit other cysteine proteases or non cysteine proteases (Dayton et aI., 1976; Nishiura et aI., 1978; Waxman and Krebs, 1978; Sakon et aI., 1982; DeMartino and CroaIl, 1984; Nakamura et aI., 1984; Lepley et aI., 1985) . MDL-28,l70 is a dipeptidyl aldehyde (CbzVaIPheH; carbamic acid, [1-[[( l-formyl-2-phenylmethyl)amino]carbonyl]-2methylpropyl]-, phenylmethyl ester that acts as a com petitive inhibitor of calpains (Mehdi et aI., 1988) . It shows inhibitory activity against ca1pain and cathepsin B but essentially no activity against other proteases (Mehdi, 1991) . Hong et aI. (1994) have shown that it reduces spectrin (a calpain substrate) degradation and infarct size in a rat model of focal ischemia.
Calpastatin or MDL-28,170 inhibited both eIF-4G degradation and calpain I autolysis in vitro. On the other hand, in vivo MDL-28,l70 blocked eIF-4G degradation but had only a partial effect on calpain I autoproteolysis. Inhibition of cal pain activity without inhibition of auto proteolysis has previously been reported in cellular stud ies (Hayashi et aI., 1991; Shea et aI., 1996; Guttmann et aI., 1997) . In our case it is likely that the in vivo brain concentrations achieved with 30 mg/kg intravenous MDL-28, 170 were significantly less than required to to tally inhibit cal pain activity. When 50 mg/kg MDL 28,170 is given intraperitoneaIly, brain levels reach 0.4 There is significant autolysis of calpain I (P = 0.001 versus e) and eIF·4G degradation (P = 0.004 versus e) after 20 minutes' ischemia. MDL·28, 170 pretreatment partially inhibits calpain I autolysis (P = 0.02 versus e; P = 0.04 versus 20-1) and significantly blocks eIF-4G degradation (P = 0.62 versus e; P = 0.01 versus 20-1) during 20 minutes of complete global ischemia.
fLmollL at 30 minutes (Shujaath Mehdi, personal com munication), whereas the concentration to achieve 50% inhibition (ICso) is I fLmoJIL for spectrin degradation in erythrocyte ghosts (Mehdi, 1991) . We attempted to in crease the dose of MDL-28,170 to 60 mg/kg intrave nously, but this dose was lethal, and this effect was not caused by the drug vehicle. This study does not exclude a role for ca\pain II activity in addition to calpain I. The in vitro calcium concentration for half-maximal proteo lytic activity is 7 to 50 fLmol/L for cal pain I and 300 to 1,000 fLmollL for calpain II Cong et aI., 1989; Edmunds et aI., 1991) . This suggests that calpain II activation can not occur in the absence of calpain I activation. Proof that degradation of eIF-4G during brain ischemia is caused exclusively by cal pain I awaits the development of a completely specific inhibitor suitable for in vivo studies or an appropriate transgenic animal. The translation initiation factor eIF-4G plays a central role in orchestrating the attachment of the mRNA to be translated to the 40S ribosomal subunit. It contains bind ing sites for eIF-4E, eIF-4A, and eIF-3 (Lamphear et aI., 1995) . In addition, mRNA vary greatly in their binding efficiency to eIF-4G (Merrick and Hershey, 1996) . Therefore, depending on the cleavage site, proteolysis of eIF-4G could have complex effects on translation effi ciency and message repertoire. Loss of the N-terminal third of eIF-4G shifts translation from capped mRNA to favor uncapped messages (Lamphear et aI., 1995; Ohl mann et aI., 1995 Ohl mann et aI., , 1996 . However it appears that once eIF-4G and its primary C-and N-terminal cleavage prod ucts (i.e., the middle third of eIF-4G [Pestova et aI., 1996] ) are lost, the cell is unable to translate any mes sages (Borman et aI., 1997) .
Eukaryotic initiation factor 4G is not the only initia tion factor altered as a consequence of ischemia and reperfusion (Hu and Wieloch, 1993; Burda et aI., 1994; Krause et aI., 1995; DeGracia et aI., 1996 DeGracia et aI., , 1997 . The overall rate of protein synthesis is dependent on the phosphorylation state of the a-subunit of eIF-2, which introduces the initiator methionyl-tRNA into the transla tion-initiation complex (Redpath and Proud, 1990) . Phosphorylation of the a-subunit of eIF-2, eIF-2a(P), prevents the replenishment of GTP onto eIF-2, whic' :� necessary for each round of translation initiation (Row lands et aI., 1988) . In several systems, increased elF-2a(P) results in decreased protein synthesis (Pain, 1996) , and Burda et aI. (1994) reported enhanced phosphoryla tion of elF-2a in brain homogenates obtained after reper fusion. Studies from our laboratory found about 24% of brain elF-2a to be phosphorylated after 90 minutes' reperfusion, and this was associated with an 83% reduc tion in initiation-dependent protein synthesis (DeGracia et aI., 1996) . Thus, although it may be possible to prevent the loss of eIF-4G by pharmacologic inhibition of cal pain, this, by itself, is unlikely to restore protein synthe SIS.
